164301-51-3
164301-51-3 結構式
基本信息
SeMapiMod (tetrahydrochloride)
Semapimod (tetrahydrochloride)(CNI-1493)
N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide,tetrahydrochloride
N,N'-bis[3-[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]-5-[(Z)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide:tetrahydrochloride
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-15509A | Semapimod tetrahydrochloride | 164301-51-3 | 5mg | 1900元 |
| 2026/06/05 | HY-15509A | Semapimod tetrahydrochloride | 164301-51-3 | 10 mg | 3250元 |
| 2026/06/05 | HY-15509A | Semapimod tetrahydrochloride | 164301-51-3 | 25 mg | 5500元 |
常見問題列表
|
IL-1β
|
IL-6
|
TNF-α
|
p38 MAPK
|
Semapimod tetrahydrochloride leads to a significant decrease of p38-MAPK phosphorylation in macrophages, proinflammatory gene expression of macrophage inflammatory protein-1alpha, interleukin-6, monocyte chemoattractant protein-1, and intercellular adhesion molecule-1, and neutrophil infiltration. Semapimod tetrahydrochloride completely abrogated nitric oxide production within the tunica muscularis.
Semapimod tetrahydrochloride desensitizes TLR signaling via its effect on the TLR chaperone gp96. Semapimod tetrahydrochloride inhibits ATP-binding and ATPase activities of gp96 in vitro (IC
50
≈0.2-0.4 μM). Semapimod tetrahydrochloride desensitizes TLR signaling via its effect on the TLR chaperone gp96.
Semapimod tetrahydrochloride (5 mg/kg; i.p; daily for 2 weeks) ameliorates endothelial dysfunction in Obese Zucker (OZ) rats.
Semapimod tetrahydrochloride restores AM-induced akt phosphorylation and cGMP production in OZ rats.
| Animal Model: | Male OZ rats |
| Dosage: | 5 mg/kg |
| Administration: | I.p; daily for 2 weeks |
| Result: | Restored endothelium-dependent vasorelaxation in OZ rats. |